Ioannis Politikos

Adult BMT Service, Memorial Sloan Kettering Cancer Center

[Antonio Jimenez Jimenez @amjimenezmd]

Excited to chair the “There’s a Donor for Everyone” session at #CBC2024, thanks to @CordBloodAssn. Honored to share the stage with @MGooptu and @ipolitikos. Big strides in HCT access, but there’s still more to do! @nmdp_org @SylvesterCancer

[Mahasweta Gooptu @MGooptu]

Wonderful sharing the stage with these rising stars! @amjimenezmd @ipolitikos

[Gunjan Shah @GunjanLShah]

Llampacas at #Tandem24 @ASTCT @DrMiguelPerales @ipolitikos

[Ioannis Politikos @ipolitikos]

Fascinating talk @DrBetofMDPhD!

[Ioannis Politikos @ipolitikos]

Thank you @BMDACCstemcell and @NeeshR0 for an outstanding Symposium and for the invitation to present our data! #sctsymposiumBMDACC #bmtsm

[Ioannis Politikos @ipolitikos]

@AndrlovaHana Congrats Hana!

[Stephen Eng, PharmD, BCOP @SEngPharmD]

First #GVHDday at #Tandem23 @GrayVPharmD @ipolitikos @ASTCT @CIBMTR #GVHDconnect4hope

[Ioannis Politikos @ipolitikos]

@AaronGoodman33 Curability of AML without transplant very low (especially non CBF AML) https://t.co/kgEKJbx9fj

[Ioannis Politikos @ipolitikos]

@ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @NMDP @CIBMTR Finally, as there is no well established calcineurin inhibitor(CNI)-free GVHD ppx regimen for #cordblood transplantion, patients with impaired renal function that are unlikely to tolerate CNI may not be ideal candidates.

[Ioannis Politikos @ipolitikos]

@ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @NMDP @CIBMTR Patients with high-titer HLA antibodies/DSA, splenomegaly, myelofibrosis may also not be suitable for #cordblood transplantation.

[Ioannis Politikos @ipolitikos]

@RahulBanerjeeMD @warren_fingrut @ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @UCSFCancer @MSKCancerCenter Very important question. I believe this is one of the objectives of the ongoing @CIBMTR CTN 1702 (CTL-ALT-D). Maybe @NMDP has updated data on attrition rates for URDs? #bmtsm

[Ioannis Politikos @ipolitikos]

@RahulBanerjeeMD @ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @UCSFCancer Both stem cell sources very important for minority patients. Quality of available haplo donors and CB units also important in donor selection. Recent data from our center by @warren_fingrut : https://t.co/1on8vUWIq7

[Ioannis Politikos @ipolitikos]

@RahulBanerjeeMD @ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein @UCSFCancer Agree! Haplo donors also significantly extend HSCT access to patients w/o SIB/MUDs. Per CTN1101 & the Spanish MAC haplo vs cord trial data, ~ 10% of HSCT pts would not have a suitable haplo donor. At our center, ~5-10% of pts getting a CB search don't have a suitable CB graft

[ASTCT @ASTCT]

We can’t wait to kick off our July #ASTCTChat today! We would like to disclose no COI with parties involved in this month's article. Remember to tag @ASTCT and #ASTCTChat to participate! @BeTheMatch
https://t.co/MsDbdpCYGA

[Ioannis Politikos @ipolitikos]

@ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein The low risk of cGVHD likely explains the low long-term healthcare burden after #cordblood transplantation. Very nice paper by @sghmd @DocBrunstein ans UMN colleagues: https://t.co/sS7bslwB5l

[Ioannis Politikos @ipolitikos]

@ASTCT @BeTheMatch @AndrewRezvani @fmilano976 @DocBrunstein Advantages of #cordblood include:
1) rapid graft availability - beneficial in urgent HSCT patients.
2) less stringent HLA-matching - important for extending transplant access to patients of non-europea or mixed ancestry.
3) low relapse rates.
4) low rates of cGVHD.

[ASTCT @ASTCT]

Today’s #ASTCTChat will discuss Guidelines for #CordBlood #Transplant. Authors include @ipolitikos, Karen Ballen, @AndrewRezvani, @fmilano976, Juliet Barker, @DocBrunstein and Leland Metheny. @BeTheMatch @ELShematology
https://t.co/Q8ASUDaDBx

[Richard J. Lin MD PhD @DrRichardJLin]

Extended Duration Letermovir Prophylaxis for Cytomegalovirus Infection after Cord Blood Transplantation in Adults https://t.co/dnn8dFNrrg @MSKCancerCenter @MSK_DeptOfMed @ipolitikos @DrMiguelPerales @GunjanLShah @GenPapaMD @sean_m_devlin Extend letermovir in all high risk patient